Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer
01 18% Average weight loss 02 9/10 Patients call it the most effective treatment to date
By enhancing satiety, appetite control, and energy balance, they support clearer, more logical decision-making around food and daily habits
VFinal volume of the sample solution, in milliliters (mL)
US$ 28.86
US$ 28.86
US$ 27.76
US$ 25.07
US$ 25.15
US$ 29.50
